Loading...

Stealth BioTherapeutics Presents Data on SBT-272 in Neurodegeneration

BOSTON, Oct. 7, 2019 /PRNewswire/ — Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced the presentation of pre-clinical data for its lead pipeline compound, SBT-272, at the 18 th Annual Northeast Amyotrophic Lateral […]